Medical Director Marketing Strategist

George Davatelis, PhD, MS

Lawrence Township, NJ

************@*****.*** 609-***-****

Medical Director/Strategist/Writer/Editor

As a medical director with many years of experience and a history of creating medical communication programs for pharmaceutical products, I look to use my medical expertise and marketing acumen to help account teams realize their client’s goals. I take pride in developing innovative tactics and finding creative solutions that often exceed client expectations, such as:

I create innovative medical marketing concepts that enable pharmaceutical companies to improve communications with their audiences

oOne concept for presenting Pfizer’s oncology pipeline at major oncology congresses brought accolades to the company

I also develop medical communication content and engagement programs for scores of advisory boards, peer-to-peer programs, launch meetings, gap analyses, literature summaries, slide sets, and training materials etc.

oTo address the issue of allergic conjunctivitis at Allergan, I developed the “beach ball” – a graphic that demonstrated how nedocromil inhibited AC through four distinct pathways, compared to competitors that affected only two inflammatory pathways

oFor another project I interviewed 12 Heme/Onc KOLS from around the world and created a series of blogs on the global state of management for people with Hodkins Lymphoma for Takeda

My scientific papers have been cited over 2,500 times and I have co-authored a research paper with Nobel Laureate Dr. Bruce Beutler and three more with Professor of Emergency Medicine at UPenn School of Medicine Dr. Charlie Pollack

I ghostwrote a white paper for EMD Serono titled “Embracing Carers;” which kicked off a collaboration with eight global caregiving organizations to launch Embracing Carers, a public private partnership designed to provide tools for policy change

I am also the co-author of a white paper for Genentech titled “Navigating Cancer Care In the Era of Personalized Medicine - A White Paper and Action Plan of the REV 2014 Forum”

For CME programs, I have written many ‘needs assessments’ for various clients and developed several unbranded disease awareness slide decks for BMS’s immunology division

Therapeutic Areas of Experience

Oncology

Cardiovascular/Hematological

Neurology/Other

Lung Cancer– NSCLC and SCLC

Breast Cancer

Leukemia and NHL

Lymphomas

Hodgkin Lymphoma

Renal Cell Carcinoma

Hepatocellular Carcinoma

Head & Neck Cancer

Prostate Cancer

Deep Vein Thrombosis

Acute Coronary Syndrome

Hypertension

RAAS System

Aortic Stenosis

Aortic Aneurysms

Atrial Fibrillation

Congestive Heart Failure

Anemia

Multiple Sclerosis

Schizophrenia/Bipolar

Migraine

Dystonia

Neuromyelitis Optica (NMO)

Allergic Conjunctivitis

Diabetic Retinopathy

T1 and T2 DM

Rheumatoid + Psoriatic arthritis

Marketing and Communication Areas of Experience

As a medical marketing strategist, I am well versed in the following tactics:

Content development (slide decks for sales training/advisory boards, articles, blogs, etc.)

Strategic planning

Congress attendance and competitive intelligent reporting

Content creation for congress booth kiosks

RFP response preparation

Pitch preparation and live presentation

Advisory board executive summaries writing

Client interaction/management

Thought leader interviews and reporting

Recent Contract Experience

I have selected some of my most recent projects to highlight my experience working with pharmaceutical products. For instance, I have done quarterly updates for Pfizer to their Congress booth oncology pipeline dating from 2012 to ESMO 2024. Other recent experiences include:

Developed infographics and clinical trial schemas for all 34 Pfizer oncology compounds

Wrote a competitive intelligence report on Epkinly for Genmab and how it compared to the other therapeutics for follicular lymphoma (FL)

Created content and executive summaries for several advisory boards for Genentech for three new hematologic oncology products for lymphoma; polivy (an ADC for DLBCL), glofitamab (a bispecific mAb for the treatment of DLBCL), and mosunetuzumab (a bispecific mAb for FL)

For Puma Biotechnology, created presentation content and wrote the executive summaries for two advisory boards on alisertib for small cell lung cancer

For Eisai, wrote a backgrounder on Eisai’s oncology portfolio

For BMS, created several unbranded infographics for immunology portfolio

For Sabal Pharmaceuticals, wrote a series of sales training modules for baclofen

Older Work History

Core-Create – Mannville NJ 2010 – 2012

Medical Director

Havas Life – Lambertville, NJ 2005 - 2010

Vice President – Senior Director of Medical Strategy

Advanced Clinical, Inc. – Lambertville, NJ 2004 - 2005

Group Director for Medical Affairs

Excerpta Medica, Inc. – Bridgewater, NJ 2002 - 2003

Senior Director of Publications

TVG, Inc. – Ft Washington, PA 2000 - 2002

Director of Scientific Communications

Allergan, Inc. – Irvine, CA 1997 - 2000

Senior Manager of Strategic Communications

Education

The Rockefeller University: Post-Doctoral Fellow in inflammatory mediators

Joan & Sanford I. Weill Medical College of Cornell University: Doctorate (PhD) in molecular biology

University of Hawaii: Master of Science degree (MS) in human genetics

Montclair State University: Bachelor of Science (BS) in biology

Blogs

“The New Normal for Pharma and HCP Interactions”

“Telemedicine in the Time of COVID”

“Protecting Brand Reputation During COVID”

“Do HCPs and Patients Believe Pharmaceutical Company Websites?”

“Improving Support for the Patient-Physician Relationship”

“The Value of Diversity in Clinical Trials”

“The Use of Social Media for Healthcare and Its Impact on Medical Marketing”

Published Editorials

“The Asilomar Process: Is It Valid?” The Scientist, 14 (7): 51, April 3, 2000.

“A DNA Summit: Let’s Do It Right.” The Scientist, 13 (20): 12, October 11, 1999.

“Asilomar2” The Scientist, 13 (8): 12, April 12, 1999.

“The Global Vaccine Initiative” The Scientist, 13 (5): March 1, 1999.

“Social Dimensions of Biotechnology” Genetic Eng News, 19 (1): 6, January 1, 1999.

Selected Peer-Reviewed Publications

Charles V. Pollack Jr., Alpesh Amin, Tomas Villanueva, Frank Peacock, Richard Summers,

George Davatelis and Scott Kaatz. Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. Curr Emerg Hosp Med Rep 2014; 2:76–89.

W. Frank Peacock, Charles V. Pollack Jr., Alpesh Amin, Tomas Villanueva, Scott Kaatz,

George Davatelis and Richard Summers. Balancing Ischemic Efficacy and Bleeding Risk in the Upstream Management of Non-ST-Segment Elevation Myocardial Infarction. Curr Emerg Hosp Med Rep 2014; 2:57–68.

Alpesh Amin, W. Frank Peacock, Scott Kaatz, Richard L. Summers, Charles V. Pollack Jr.,

George Davatelis and Tomas Villanueva. How to Develop and Validate Institutional ACS Protocols: Guidelines and Transitions of Care in ACS Management. Curr Emerg Hosp Med Rep 2014; 2:69–75.

Minano FJ, Sancibrian M, Vizcaino M, Davatelis G, Fahey T, Sherry B, Cerami A, Myers RD. Macrophage Inflammatory Protein-1: Unique Action on the Hypothalamus to Evoke Fever. Brain Research Bulletin. 1990; 24:849.

Davatelis G, Wolpe SD, Sherry B, Dayer JM, Chicheportiche, and Cerami A. Macrophage Inflammatory Protein-1: a prostaglandin-independent endogenous pyrogen. Science. 1989 Feb 24;243(4894 Pt 1):1066-8.

Wolpe SD, Sherry B, Juers D, Davatelis G, Wurt RW, and Cerami A. Identification and Characterization of Macrophage Inflammatory Protein-2. Proceedings of the National Academy of Sciences USA. 1989; 86:612.

Davatelis G, Tekamp-Olson P, Wolpe SD, Hermsen K, Leudke C, Gallegos C, Coit D, Merryweather J, and Cerami A. Cloning and Characterization of a cDNA for Murine Macrophage Inflammatory Protein (MIP), a Novel Monokine with Inflammatory and Chemokinetic Properties. J Experimental Medicine 1989; 167:1939.

Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, Moldawer LL, Nathan CF, Lowry SF, and Cerami A. Macrophages Secrete a Novel Heparin-Binding Protein with Neutrophil Chemokinetic Properties. Journal of Experimental Medicine. 1989; 167:570.

Contact this candidate